Finance Watch: Alphamab's $100m Series A Continues Theme Of Big Investments In China Biopharma

The Suzhou-based drug developer brings in new cash as US venture deals take a holiday. Also, France's Genfit may go public in the US, Taiwan Liposome launches its IPO, and Bioblast's strategic review ends in a reverse merger.

Finance Watch

The US may be in Thanksgiving mode, but companies in other parts of the world continue to come forward with venture capital investment news, including China's Alphamab Oncology with a $100m Series A round.

Suzhou-based Alphamab said on Nov. 16 that the proceeds will fund global clinical development of its cancer drug pipeline, including...

More from Financing

More from Business